CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-consumer weight-management offerings, while both companies reported higher-than-expected second-quarter results Wednesday.
The collaboration with drugmaker Lilly will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy via the CVS Health app, the retail pharmacy chain said. The tie-up promises to offer transparent pricing, including reimbursed and self-pay options, for the drugs by early in the fourth quarter.
Lilly didn't immediately respond to' request for comment on the collaboration.
The collaboration is part of a broader effort by CVS to enhance its DTC weight-management program, with MinuteClinic digital weight-loss visits lowered to $29, among other things. CVS Pharmacy offers all Food and Drug Administration-approved Glucagon-like peptide-1s, whether through insurance or cash-pay options.
Separately, CVS reported that its second-quarter adjusted earnings rose to $2.58 a share from $1.81 a year earlier, exceeding the FactSet-polled consensus of $1.85. Revenue grew 7.3% to $106.1 billion, topping Wall Street's $100.03 billion views.
The company now expects 2026 adjusted EPS between $7.90 and $8.10, compared with its prior outlook range of $7.30 to $7.50 and above the Street's $7.45 forecast. The updated guidance accounts for gains in the healthcare benefits and pharmacy and consumer wellness segments "while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds" CVS said in an earnings release.
Separately, Lilly reported non-GAAP EPS of $8.38 for the June quarter, up from $6.31 a year earlier, surpassing the FactSet-polled consensus of $6.17. Revenue surged 48% to $22.97 billion, while analysts projected $20.69 billion.
The drugmaker raised its 2026 revenue outlook to a range of $85 billion to $87 billion from the previous guidance of $82 billion to $85 billion. The company narrowed its full-year non-GAAP EPS forecast to between $35.50 and $36.50 from its previous range of $35.50 to $37. Analysts are looking for full-year non-GAAP EPS of $35.16 on revenue of $85.39 billion.
"(The second quarter) continued Lilly's strong momentum," Chief Executive David Ricks said on an earnings call, according to a FactSet transcript. "We delivered robust revenue across all key products and major geographies."
Lilly shares were up 4.1% in Wednesday afternoon trade, while CVS fell 5.1%.
Price: $99.45, Change: $-4.98, Percent Change: -4.76%
